Clinical outcomes of persistent cough following coronavirus disease 2019 infection: A 1-year retrospective cohort study.

IF 2.1 Q3 ALLERGY
Asia Pacific Allergy Pub Date : 2025-09-01 Epub Date: 2025-03-17 DOI:10.5415/apallergy.0000000000000188
Sang Pyo Lee, Sung-Yoon Kang
{"title":"Clinical outcomes of persistent cough following coronavirus disease 2019 infection: A 1-year retrospective cohort study.","authors":"Sang Pyo Lee, Sung-Yoon Kang","doi":"10.5415/apallergy.0000000000000188","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cough is one of the multiple prolonged symptoms observed in patients who had coronavirus disease 2019 (COVID-19) infection.</p><p><strong>Objective: </strong>We assessed the clinical outcomes and identified factors contributing to cough persistence in patients post-COVID-19.</p><p><strong>Methods: </strong>This retrospective cohort study included adults who visited a specialist cough clinic between 2022 and 2023. All participants underwent systematic investigation and treatment for persistent cough. Cough persistence was assessed at the 2- and 12-month follow-ups. Participants were classified as having persistent cough if they had a current troublesome cough at the 2- and 12-month follow-ups, and a cough severity visual analog scale (VAS) score change below 30.</p><p><strong>Results: </strong>Sixty-six patients (mean age 48.7 years; 72.7% women) were analyzed and divided into 2 groups: persistent cough (33.3%) and remitted cough (66.7%). The persistent cough group had a significantly higher prevalence of abnormal laryngeal sensation, sputum production, breathing difficulty, and airway eosinophilia; their VAS score changes at 2 months were also lower. Multivariable analyses indicated associations between persistent cough at 1 year and factors such as airway eosinophilia (adjusted odds ratio [aOR], 6.78), abnormal laryngeal sensation (aOR, 6.42), and low cough VAS reduction (aOR, 1.05).</p><p><strong>Conclusion: </strong>Persistent cough remained a significant issue for one-third of the patients after COVID-19. The clinical features commonly observed in chronic cough were also present in those who have experienced COVID-19, which contributed to prolonged cough. These findings underscore the need for systematic assessment and tailored treatment strategies to effectively manage persistent cough in patients post-COVID-19.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 3","pages":"186-191"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419411/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cough is one of the multiple prolonged symptoms observed in patients who had coronavirus disease 2019 (COVID-19) infection.

Objective: We assessed the clinical outcomes and identified factors contributing to cough persistence in patients post-COVID-19.

Methods: This retrospective cohort study included adults who visited a specialist cough clinic between 2022 and 2023. All participants underwent systematic investigation and treatment for persistent cough. Cough persistence was assessed at the 2- and 12-month follow-ups. Participants were classified as having persistent cough if they had a current troublesome cough at the 2- and 12-month follow-ups, and a cough severity visual analog scale (VAS) score change below 30.

Results: Sixty-six patients (mean age 48.7 years; 72.7% women) were analyzed and divided into 2 groups: persistent cough (33.3%) and remitted cough (66.7%). The persistent cough group had a significantly higher prevalence of abnormal laryngeal sensation, sputum production, breathing difficulty, and airway eosinophilia; their VAS score changes at 2 months were also lower. Multivariable analyses indicated associations between persistent cough at 1 year and factors such as airway eosinophilia (adjusted odds ratio [aOR], 6.78), abnormal laryngeal sensation (aOR, 6.42), and low cough VAS reduction (aOR, 1.05).

Conclusion: Persistent cough remained a significant issue for one-third of the patients after COVID-19. The clinical features commonly observed in chronic cough were also present in those who have experienced COVID-19, which contributed to prolonged cough. These findings underscore the need for systematic assessment and tailored treatment strategies to effectively manage persistent cough in patients post-COVID-19.

Abstract Image

2019冠状病毒感染后持续咳嗽的临床结果:一项为期1年的回顾性队列研究
背景:咳嗽是2019冠状病毒病(COVID-19)感染患者的多种长期症状之一。目的:我们评估covid -19后患者的临床结局,并确定影响咳嗽持续的因素。方法:这项回顾性队列研究包括在2022年至2023年间访问过专科咳嗽诊所的成年人。所有的参与者都接受了系统的调查和治疗。在2个月和12个月的随访中评估咳嗽持续性。如果参与者在2个月和12个月的随访中有持续咳嗽,并且咳嗽严重程度视觉模拟量表(VAS)评分低于30分,则将其归类为持续性咳嗽。结果:66例患者(平均年龄48.7岁,女性72.7%)分为持续咳嗽组(33.3%)和缓解咳嗽组(66.7%)。持续咳嗽组喉部感觉异常、咳痰、呼吸困难、气道嗜酸性粒细胞增多的发生率明显高于持续咳嗽组;2个月时的VAS评分变化也较低。多变量分析显示,持续咳嗽1年与气道嗜酸性粒细胞增多(校正优势比[aOR], 6.78)、喉感觉异常(aOR, 6.42)和低咳嗽VAS降低(aOR, 1.05)等因素相关。结论:三分之一的新冠肺炎患者仍存在持续咳嗽问题。慢性咳嗽中常见的临床特征也存在于那些经历过COVID-19的人身上,这导致了长时间的咳嗽。这些发现强调需要进行系统评估和量身定制的治疗策略,以有效管理covid -19后患者的持续咳嗽。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
5.90%
发文量
33
期刊介绍: Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信